Vimarsana
Biggest News Aggregation in the World

Solid Tumour News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solid Tumour. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solid Tumour Today - Breaking & Trending Today

Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen - Vimarsana News

Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen

Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate...

Storm doses first patient with solid tumour drug candidate - Vimarsana News

Storm doses first patient with solid tumour drug candidate

Candidate is first molecule targeting an RNA methyltransferase enzyme to enter development - News - PharmaTimes

Surat Hematology Centre celebrates 50 successful Bone-Marrow Transplants - A landmark achievement by one of the leading Hematology Centres in South Gujarat - Vimarsana News

Surat Hematology Centre celebrates 50 successful Bone-Marrow Transplants - A landmark achievement by one of the leading Hematology Centres in South Gujarat

New Delhi [India], October 21 (ANI/SRV): Surat Hematology Centre, one of the leading Hematology centres in Surat, recently celebrated a landmark achievement of the 50th successful Bone Marrow Transplant. The Centre specialises in Bone Marrow Transplants and the treatment of blood disorders in the South Gujarat region and has some of the best Hematologists in Surat as their founders. The centre has achieved this remarkable feat in a very short period of time. The centre was established by two visionaries sharing the same passion, Dr Hasmukh R Balar and Dr Dharmesh Vaghasiya, both being Hemato-O...

First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma - Vimarsana News

First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma

QBiotics Group Limited (QBiotics), a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has dosed the first patient in the Phase Ib/IIa clinical trial of the company's lead oncology molecule, tigilanol tiglate in combination with MSD's immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) for patients with unresectable melanoma, the deadliest form of skin cancer.

Source: yahoo.com
Avacta gets MHRA green-light to start phase I trial for 'pro-drug' chemotherapy - Vimarsana News

Avacta gets MHRA green-light to start phase I trial for 'pro-drug' chemotherapy

AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta's pre|CISION chemistry - News - PharmaTimes